Thu.Aug 22, 2024

article thumbnail

Secondary packaging for sterile injectables: Overcoming today’s design challenges

Pharmaceutical Technology

Packaging experts discuss emerging challenges in secondary packaging design for injectables that balance sustainability with end-user needs.

Packaging 246
article thumbnail

Updated COVID shots from Pfizer, Moderna cleared by FDA

Bio Pharma Dive

The approval of both reformulated messenger RNA vaccines, which are designed to target the KP.2 virus strain, comes just ahead of the fall and winter seasons.

RNA 252
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ICMR invites researchers to develop evidence-based guidelines for empirical use of antibiotics

AuroBlog - Aurous Healthcare Clinical Trials blog

The Indian Council of Medical Research (ICMR) has announced a Request for Expressions of Interest (EoI) aimed at inviting researchers, academicians, and scientists to participate in the formulation of evidence-based guidelines for the empirical use of antibiotics in the management of sepsis, dental infections, and vaginal discharge.

Research 151
article thumbnail

Versant reimagines its Chinook success with newest startup launch

Bio Pharma Dive

Borealis Biosciences launches with money from Novartis, which last year bought the biotech’s predecessor for a pair of drugs that treat a rare kidney disorder.

Drugs 157
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Surprise Alzheimer’s Finding: Brain’s Support Cells May Be Fueling Disease

AuroBlog - Aurous Healthcare Clinical Trials blog

Neurons aren’t the only brain cells producing the proteins associated with Alzheimer’s disease, a new study of mouse models reveals. It turns out that cells supporting neurons contribute to this process too. Amyloid beta proteins occur naturally in our brains, but have long, and now controversially, been associated with Alzheimer’s disease.

Protein 134
article thumbnail

FDA defends med device chief’s tenure after report raises ethics concerns

Bio Pharma Dive

The FDA backed Jeff Shuren, the agency’s former CDRH leader, amid questions raised by The New York Times. Still, a spokesperson said the FDA has advised Shuren to take greater caution in managing recusal obligations.

144
144

More Trending

article thumbnail

UK approves Leqembi, but reimbursement may not follow

Bio Pharma Dive

Leqembi’s benefits are “too small to justify the significant cost to the NHS,” said the head of a UK agency in charge of determining medicine reimbursement.

Medicine 144
article thumbnail

Innovent’s Dupert approved in China to treat lung cancer

Pharmaceutical Technology

China's National Medical Products Administration (NMPA) has granted approval for Innovent Biologics’ Kristen rat sarcoma (KRAS) G12C inhibitor, Dupert (fulzerasib), to treat advanced non-small cell lung cancer (NSCLC) in adults.

article thumbnail

Despite looming BIOSECURE threat, pharma contracting giant WuXi Bio scoops up new projects

Fierce Pharma

Despite some Western drugmakers’ concerns around working with Chinese manufacturers in light of the looming BIOSECURE Act, WuXi Biologics continues to pick up a steady stream of new contracts. | Despite some Western drugmakers’ concerns around working with Chinese manufacturers in light of the looming BIOSECURE Act, WuXi Biologics continues to pick up a steady stream of new contracts, the company said.

article thumbnail

Heidelberg Pharma gets grant for methods for enhancing car immune cell acceptance using anti-cd5 adcs

Pharmaceutical Technology

Discover Heidelberg Pharma AG's innovative patent enhancing CAR T-cell therapy for cancer and autoimmune diseases using anti-CD5 antibody drug conjugates for better outcomes.

Antibody 130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

An Extra Layer of Transparency and Accountability

Pharmaceutical Commerce

In the final part of his Pharma Commerce video interview, Matt Hawkins, CaryHealth’s Chief Technology Officer, comments on the importance of mitigating security risks, along with ways to take action.

100
100
article thumbnail

Larimar Therapeutics gets grant for methods for measuring frataxin protein activity and modulation

Pharmaceutical Technology

Discover Larimar Therapeutics' groundbreaking patent on measuring frataxin (FXN) protein activity. Learn how this innovative method could impact research and therapies.

Protein 130
article thumbnail

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

BioPharma Reporter

ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients.

article thumbnail

Syndax Pharmaceuticals gets grant for patient selection for hdac inhibitor combination cancer therapy

Pharmaceutical Technology

Discover how Syndax Pharmaceuticals' new patent enhances cancer treatment by selecting patients for combination therapy using immune cell markers in blood samples.

130
130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

GLP-1 Drugs Mounjaro, Zepbound, Wegovy Back in Stock After Extended Shortages

XTalks

After a nearly two-year-long shortage, the US Food and Drug Administration (FDA) announced earlier this month that Eli Lilly’s GLP-1 diabetes drug Mounjaro (tirzepatide) is back on shelves along with weight loss version Zepbound. A few days later, GLP-1 drug rival Novo Nordisk announced that four out of five dose strengths of its GLP-1 obesity drug Wegovy (0.5 mg, 1 mg, 1.7 mg and 2.4 mg) are now available in the US.

Drugs 97
article thumbnail

Avadel Pharmaceuticals gets grant for gamma-hydroxybutyrate formulations for treating narcolepsy symptoms

Pharmaceutical Technology

Discover Avadel Pharmaceuticals' new patent for GHB formulations, enhancing narcolepsy treatment with a tailored dosage regimen for effective symptom relief.

130
130
article thumbnail

FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds

Fierce Pharma

The FDA is once again gathering external experts to scrutinize PD-1 inhibitors as a group. | The FDA will hold an advisory committee meeting on Sept. 26 to consider whether approvals for checkpoint inhibitors in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma—as well as in esophageal squamous cell carcinoma (ESCC)—should be restricted based on a tumor’s PD-L1 expression.

Drugs 87
article thumbnail

CSPC Pharmaceutical Group gets grant for lsd1 inhibitor compound and its crystal form

Pharmaceutical Technology

Discover CSPC Pharmaceutical's groundbreaking patent for compound III, an LSD1 inhibitor, with a novel crystal form aimed at treating small cell lung cancer.

130
130
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer

pharmaphorum

BMS looks ahead to April verdict from FDA on Opdivo/Yervoy combination as first-line treatment for unresectable hepatocellular carcinoma.

102
102
article thumbnail

Antisense Therapeutics gets grant for method for treating muscular dystrophy using oligonucleotides

Pharmaceutical Technology

Discover Antisense Therapeutics' groundbreaking patent for treating muscular dystrophy, enhancing muscle function with a unique oligonucleotide method.

130
130
article thumbnail

Breaking News: Lecanemab approved in UK but unavailable on NHS

BioPharma Reporter

Eisai and Biogenâs new Alzheimerâs treatment, lecanemab, received a green light from UK regulators, marking a significant advance in treating early-stage Alzheimerâs disease.

article thumbnail

Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD

Pharmaceutical Technology

A US FDA advisory committee (AdComm) is set to evaluate Zynquista as an adjunct therapy for type 1 diabetes and chronic kidney disease (CKD).

130
130
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Navigating Accessibility: How New Global Accessibility Laws Affect Pharmaceutical Companies

Intouch Solutions

Digital accessibility is essential to your brand because it ensures that everyone, no matter their ability or use of assistive technology, can access and use your digital properties. Creating accessible digital properties (websites, apps, emails, banners, PDFs, videos, etc.) should be top of mind for pharmaceutical companies that want to stay competitive and legally compliant.

article thumbnail

CTI announces partnership for oncology drug development

Pharmaceutical Technology

CTI Clinical Trial & Consulting Services and Crown Bioscience have announced a strategic partnership to boost oncology drug development.

article thumbnail

H1 Connect links doctors to global humanitarian missions

Outsourcing Pharma

H1's decision to partner with GRM for this critical initiative in Ukraine was driven by a strong commitment to harness the power of global healthcare networks to provide humanitarian aid in regions that need it most.

Doctors 87
article thumbnail

FDA accepts BMS’ sBLA for Opdivo-Yervoy combo for HCC

Pharmaceutical Technology

The FDA) has accepted the sBLA filed by BMS for Opdivo (nivolumab) and Yervoy (ipilimumab) to treat unresectable hepatocellular carcinoma.

130
130
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

FDA approval of Regeneron’s myeloma drug delayed due to manufacturing issues

BioPharma Reporter

The US regulator has confirmed a delay to the approval of linvoseltamab while a manufacturing issue is resolved with a third-party provider.

article thumbnail

Touchlight to supply GMP dbDNA for UK Zika vaccine study

Pharmaceutical Technology

Touchlight collaborated with the University of Nottingham to supply GMP-grade dbDNA tech to develop next-gen vaccine for the Zika virus.

article thumbnail

SynaptixBio awarded £2m BioMedical Catalyst grant from Innovate UK

Pharma Times

The grant will support clinical trials of rare disease therapy for leukodystrophy

article thumbnail

Eisai’s Leqembi deemed too costly for NHS

Pharmaceutical Technology

Despite its marketing approval, Leqembi’s cost effectiveness falls short of NICE’s standards to justify wide range use in the UK.

Marketing 130
article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.